Ann: Science Series CHECKvacc, page-133

Hey!

I missed this, but that's 2/2 so far for the boy!

Read my linked post. Called this well before it happened. IMU pre-treating mice to find potential therapies then flogging them off to shareholders as solid science. Major red flag.

HER-vaxx fail 1. Was never correctly tested against Herceptin, and Enhertu is the game changer for that space.
CHECKVacc fail 2. No clinical response even from IT. B-cell epitopes are not effective. Cancer is difficult to kill, you need strong cytotoxic agents. Also, first signs of CF33 ineffectiveness.



CF33 is very much looking like it is going down the same path. No clinical efficacy through IV. Limited efficacy as IT, and it's not clear whether the efficacy is mono or combo. Even if CR/PR as mono agent through IT, the application in the real world is low. Cholangiocarcinoma is a relatively tiny market and is mostly dominated by targetted therapies. Unless you manage to get some meaningful data, IMU MC is going to drop significantly.